Bay Colony Advisory Group, Inc D Intellia Therapeutics, Inc. Transaction History

Bay Colony Advisory Group, Inc D

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$34.58 - $46.03 $24,620 - $32,773	-712 Reduced 12.07%	5,188 $211,000
Q1 2023 Apr 27, 2023	SELL	$33.3 - $44.82 $3,329 - $4,482	-100 Reduced 1.67%	5,900 $219,000
Q3 2022 Oct 27, 2022	BUY	$53.92 - $71.7 $18,872 - $25,095	350 Added 6.19%	6,000 $336,000
Q2 2022 Aug 08, 2022	BUY	$38.49 - $76.21 $17,320 - $34,294	450 Added 8.65%	5,650 $366,000
Q1 2022 Apr 28, 2022	BUY	$58.27 - $118.99 $14,567 - $29,747	250 Added 5.05%	5,200 $378,000
Q4 2021 Jan 28, 2022	BUY	$100.76 - $138.36 $40,304 - $55,344	400 Added 8.79%	4,950 $585,000
Q4 2020 Feb 02, 2021	BUY	$18.83 - $63.53 $85,676 - $289,061	4,550 New	4,550 $248,000

316

91.7M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $722M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Bay Colony Advisory Group, Inc D, based on Form 13F filings with the SEC.

Stay updated on Bay Colony Advisory Group, Inc D with notifications on news.